Sino Biopharmaceutical Limited provided earnings guidance for the year ended December 31, 2018. The board of directors of the Company announced that the profit of the Group for the year ended 31 December 2018 is expected to increase significantly as compared with that for the year ended 31 December 2017. The profit attributable to the owners of the parent for year 2018 is expected to increase to a range of approximately RMB 8,908.37 million to approximately RMB 9,283.71 million (year 2017: approximately RMB 2,170.95 million). The significant increase in the profit attributable to the owners of the parent is mainly attributable to certain profit or loss items that are required to be recognized in the accounts of the Company in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") following the acquisition ("Acquisition") of 24% interest in Beijing Tide Pharmaceutical Co. Ltd. ("Beijing Tide") by the Company in 2018. Details of the Acquisition have been set out in the announcements of the Company dated 5 January 2018 and 1 March 2018, respectively, and the circular of the Company dated 26 January 2018.